Bausch + Lomb Announces Second-Quarter 2024 Results

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Insights

Bausch + Lomb's Q2 2024 results demonstrate strong performance across all segments, with total revenue reaching $1.216 billion, a 17% increase year-over-year. The company's constant currency growth of 20% is particularly impressive, indicating robust underlying business momentum.

Key highlights include:

Vision Care segment grew 11% on a constant currency basis, driven by dry eye products and contact lenses.
Surgical segment increased 9%, boosted by equipment, consumables and premium IOLs.
Pharmaceuticals segment surged 61%, primarily due to the XIIDRA acquisition and MIEBO launch.

However, the $151 million net loss is concerning, mainly attributed to higher costs and increased taxes. The $209 million Adjusted EBITDA represents a 16.8% margin, which is relatively low for the industry.

The raised full-year guidance suggests management's confidence in continued growth. The projected 16-18% constant currency growth for 2024 is ambitious but appears achievable given the current trajectory.

Investors should monitor the company's ability to improve profitability while maintaining growth, especially considering the increased interest expenses from recent acquisitions.

Bausch + Lomb's Q2 results reflect a company capitalizing on market trends and strategic acquisitions. The 11% growth in Vision Care aligns with the increasing prevalence of dry eye and demand for advanced contact lenses. The dry eye market, in particular, is experiencing rapid expansion due to factors like increased screen time and aging populations.

The Surgical segment's 9% growth indicates a recovery in elective procedures post-pandemic and a shift towards premium options. This trend is likely to continue as healthcare systems normalize operations.

The Pharmaceuticals segment's exceptional 61% growth, largely driven by XIIDRA and MIEBO, showcases the company's successful expansion in the prescription eye care market. This diversification reduces reliance on consumer products and positions Bausch + Lomb as a more comprehensive eye health player.

The raised guidance suggests management's optimism about market conditions and the company's competitive position. However, investors should be aware of potential challenges such as healthcare policy changes, competitive pressures in key markets and the need for continued innovation to maintain market share.

Overall, Bausch + Lomb's performance indicates a company well-positioned to benefit from growing global demand for eye health products across various categories.

07/31/2024 - 07:00 AM

Revenue of $1.216 Billion
GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million
Adjusted EBITDA (non-GAAP)¹ of $209 Million
Revenue Grew 17% as Reported and 20% on a Constant Currency¹ Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments
Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP)¹ Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results.

“Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitment to innovation that defined our past and will dictate our future,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “That commitment was on full display in the second quarter, with the approval or launch of three innovative products across three distinct businesses, announced over 12 days.”

Select Second-Quarter Company Highlights

Delivered robust growth across all segments, geographies and key franchises
Strengthened dry eye category leadership with growth across Rx and OTC products
Launched several innovative new products, including BLINK™ NutriTears^®, INFUSE^® for Astigmatism and enVista^® Envy™

Second-Quarter 2024 Revenue Performance

Total reported revenue was $1.216 billion for the second quarter of 2024, as compared to $1.035 billion in the second quarter of 2023, an increase of $181 million, or 17%. Excluding the unfavorable impact of foreign exchange of $27 million, revenue increased by approximately 20% on a constant currency¹ basis compared to the second quarter of 2023.

Revenue by segment was as follows:

Second-Quarter 2024

(in millions)	Three Months Ended June 30		Reported Change	Reported Change	Change at Constant Currency¹ (non-GAAP)
	2024	2023

Total Bausch + Lomb Revenue	$1,216	$1,035	$181	17%	20%

Vision Care	$697	$646	$51	8%	11%
Surgical	$209	$195	$14	7%	9%
Pharmaceuticals	$310	$194	$116	60%	61%

Vision Care Segment

Vision Care segment revenue was $697 million for the second quarter of 2024, as compared to $646 million for the second quarter of 2023, an increase of $51 million, or 8%. Excluding the unfavorable impact of foreign exchange of $20 million, segment revenue increased on a constant currency¹ basis by approximately 11% compared to the second quarter of 2023, primarily due to sales from the dry eye portfolio, LUMIFY^® and eye vitamins within the consumer eye care business, and daily SiHy lenses and ULTRA^® within the contact lens business.

Surgical Segment

Surgical segment revenue was $209 million for the second quarter of 2024, as compared to $195 million for the second quarter of 2023, an increase of $14 million, or 7%. Excluding the unfavorable impact of foreign exchange of $4 million, segment revenue increased on a constant currency¹ basis by approximately 9% compared to the second quarter of 2023, primarily due to increased demand for equipment and consumables, along with implantables, driven by the premium IOL portfolio.

Pharmaceuticals Segment

Pharmaceuticals segment revenue was $310 million for the second quarter of 2024, as compared to $194 million for the second quarter of 2023, an increase of $116 million, or 60%. Excluding the unfavorable impact of foreign exchange of $3 million, segment revenue increased on a constant currency¹ basis by approximately 61% compared to the second quarter of 2023, primarily due to the XIIDRA^® acquisition, strong launch performance of MIEBO^® and continued growth in U.S. Generics and International Pharmaceuticals.

Operating Results

Operating income was $26 million for the second quarter of 2024, as compared to an operating income of $43 million for the second quarter of 2023, a decrease of $17 million. The change was largely driven by higher selling, advertising and promotion costs, primarily attributable to XIIDRA and the launch of MIEBO and amortization expense, partially offset by the increase in gross profit contribution.

Net Loss

Net loss attributable to Bausch + Lomb Corporation for the second quarter of 2024 was $151 million, as compared to $32 million for the second quarter of 2023, an unfavorable change of $119 million. The change was primarily due to the increase in the provision for income taxes and interest expense and the decrease in operating results noted above.

Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP)¹ for the second quarter of 2024 was $45 million, as compared to $65 million for the second quarter of 2023, a decrease of $20 million.

Cash from Operations

Cash flow from operations for the second quarter of 2024 was $15 million, as compared to cash flow used in operations of $24 million for the second quarter of 2023, an increase of $39 million. Cash flow from operations was positively impacted by increased gross profit, primarily driven by XIIDRA, partially offset by increased interest payments, timing of collections and an increase in inventory.

Earnings Per Share

GAAP Earnings Per Share (“EPS”) Basic and Diluted attributable to Bausch + Lomb Corporation for the second quarter of 2024 was ($0.43), as compared to ($0.09) for the second quarter of 2023. Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)¹ for the second quarter of 2024 was $0.13, as compared to $0.18 for the second quarter of 2023.

Adjusted EBITDA (non-GAAP)¹

Adjusted EBITDA (non-GAAP)¹ was $209 million for the second quarter of 2024, as compared to $179 million for the second quarter of 2023, an increase of $30 million, primarily due to the increase in sales, as noted above, partially offset by an investment in launch products, including MIEBO and XIIDRA.

2024 Financial Outlook²

Bausch + Lomb raised revenue and Adjusted EBITDA (non-GAAP)¹ guidance for the full year of 2024 as follows:

	As of May 1, 2024	As of July 31, 2024³

Full-year revenue	$4.600 – $4.700 billion	$4.700 – $4.800 billion
	~13-15% constant currency growth¹	~16-18% constant currency growth¹

Full-year Adjusted EBITDA (non-GAAP)¹	$840 – $890 million	$850 – $900 million

Full-year revenue foreign exchange headwinds	-$90 million	-$90 million

Other than with respect to GAAP revenue, the company only provides guidance on a non-GAAP basis. The company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP)¹ to GAAP net income (loss) attributable to Bausch + Lomb Corporation or of forward-looking constant currency revenue growth¹ to reported revenue growth, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, could result in the projected GAAP measure or ratio being materially different or less than the projected non-GAAP measure or ratio. These statements represent forward-looking information and may represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the Forward-looking Statements section of this news release.

Balance Sheet Highlights

Bausch + Lomb’s cash, cash equivalents and restricted cash were $302 million at June 30, 2024
Basic weighted average shares outstanding for the second quarter of 2024 were 351.8 million, and diluted weighted average shares outstanding for the second quarter of 2024 were 353.0 million⁴

Conference Call Details

Date:			Wednesday, July 31, 2024
Time:			8 a.m. ET
Webcast:			https://www.webcaster4.com/Webcast/Page/2883/49632
Participant Event Dial-in:			+1 (888) 506-0062 (North America) +1 (973) 528-0011 (International)
Participant Access Code:			207157
Replay Dial-in:			+1 (877) 481-4010 (North America) +1 (919) 882-2331 (International)
Replay Passcode:			49632 (replay available until August 14, 2024)

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

Forward-looking Statements

This news release contains forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”), which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “projects,” “predicts,” “forecasts,” “should,” “could,” “would,” “may,” “might,” “will,” “strive,” “believes,” “estimates,” “potential,” “target,” “guidance,” “outlook,” or “continue” and positive and negative variations or similar expressions and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. Forward-looking statements include statements regarding Bausch + Lomb’s future prospects and performance, including the company’s 2024 full-year guidance. These forward-looking statements, including the company’s full-year guidance, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission (“SEC”) and the Canadian Securities Administrators (the “CSA”) (including the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2023 (filed with the SEC and CSA on Feb. 21, 2024) and its most recent quarterly filings), which factors are incorporated herein by reference. They also include risks and uncertainties respecting the proposed plan to spin off or separate Bausch + Lomb from Bausch Health Companies Inc. (“BHC”), including the expected benefits and costs of the spinoff transaction, the expected timing of completion of the spinoff transaction and its terms (including the expectation that the spinoff transaction will be completed following the achievement of targeted net leverage ratios, subject to receipt of applicable shareholder and other necessary approvals and other factors (including those described in BHC’s public filings)), the ability to complete the spinoff transaction considering the various conditions to the completion of the spinoff transaction (some of which are outside the company’s and BHC’s control, including conditions related to regulatory matters and receipt of applicable shareholder and other approvals), the impact of any potential sales of the company’s common shares by BHC, that market or other conditions are no longer favorable to completing the transaction, that applicable shareholder, stock exchange, regulatory or other approval is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the spinoff transaction, diversion of management time on spinoff transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the spinoff transaction, the structure of the spinoff transaction and related distribution, the qualification of the spinoff transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the company and BHC to satisfy the conditions required to maintain the tax-free status of the spinoff transaction (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the spinoff transaction, the potential dis-synergy costs resulting from the spinoff transaction, the impact of the spinoff transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the company is engaged in, behavior of customers, suppliers and competitors, technological developments and legal and regulatory rules affecting the company’s business. In particular, the company can offer no assurance that any spinoff transaction will occur at all, or that any spinoff transaction will occur on the terms and timelines anticipated by the company and BHC. They also include risks and uncertainties respecting the acquisition of XIIDRA^® and certain other ophthalmology assets, including risks that the company may not realize the expected benefits of that transaction on a timely basis or at all and risks relating to increased levels of debt as a result of debt incurred to finance such transaction, including in regards to compliance with our debt covenants. Finally, they also include, but are not limited to, risks and uncertainties caused by or relating to adverse economic conditions and other macroeconomic factors, including inflation, slower growth or a potential recession, which could adversely impact our revenue, expenses and resulting margins, and economic factors over which we have no control, including inflationary pressures as a result of historically high domestic and global inflation and otherwise, interest rates, foreign currency rates, and the positional effect of such factors on revenue, expenses and resulting margins. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including, without limitation, the assumption that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. In addition, management has also made certain assumptions regarding our 2024 full-year guidance with respect to expectations regarding base performance growth, expectations regarding performance of certain of our key products (including XIIDRA^® and MIEBO^®), currency impact, run-rate dis-synergies and inflation, expectations regarding adjusted gross margin (non-GAAP), adjusted SG&A expense (non-GAAP) and the company’s ability to continue to manage such expense in the manner anticipated, interest expense, adjusted tax rate and full year capex and the anticipated timing and extent of the company’s R&D expense.

Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Links provided in this news release are solely for information purposes and do not constitute Bausch + Lomb affirming any forward-looking statements contained in the linked content.

Non-GAAP Information

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP financial measures and ratios. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of the company’s performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance and the valuation of the company. In addition, these non-GAAP measures and ratios address questions the company routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the company has determined that it is appropriate to make this data available to all investors.

These measures and ratios do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to similar non-GAAP measures and ratios of other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historic non-GAAP financial measures and ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the tables below.

Specific Non-GAAP Measures

EBITDA and Adjusted EBITDA

EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest, income taxes, depreciation and amortization. Adjusted EBITDA (non-GAAP) is EBITDA (non-GAAP) further adjusted for the items described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the company measures the business internally and sets operational goals and incentives. In particular, the company believes that Adjusted EBITDA (non-GAAP) focuses management on the company’s underlying operational results and business performance. As a result, the company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the company’s executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization and further adjusted for the following items:

Asset impairments: The company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The company believes that the adjustments of these items correlate with the sustainability of the company’s operating performance. Although the company excludes impairments of intangible assets from measuring the performance of the company and its business, the company believes that it is important for investors to understand that intangible assets contribute to revenue generation.
Restructuring, integration and transformation costs: The company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the completion of the Bausch + Lomb IPO, as the company prepares for post-separation operations, the company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the company’s restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course charges include third-party advisory costs, as well as certain compensation-related costs (including costs associated with changes in our executive officers, such as the severance costs associated with the departure of the company’s former CEO and the costs associated with the appointment of the company’s current CEO). Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the company’s operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
Acquisition-related costs and adjustments excluding amortization of intangible assets: The company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the company excludes the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the company’s acquisitions, as well as the nature of the agreed-upon consideration.
Share-based compensation: The company excludes costs relating to share-based compensation. The company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.
Separation costs and separation-related costs: The company has excluded certain costs incurred in connection with activities taken to: (i) separate the Bausch + Lomb business from the remainder of BHC and (ii) register the Bausch + Lomb business as an independent publicly traded entity. Separation costs are incremental costs directly related to effectuating the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, legal, audit and advisory fees, talent acquisition costs and costs associated with establishing a new Board of Directors and Audit Committee. Separation-related costs are incremental costs indirectly related to the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, IT infrastructure and software licensing costs, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the company’s operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
Other Non-GAAP adjustments: The company also excludes certain other amounts, including IT infrastructure investment, litigation and other matters, gain/(loss) on sales of assets and certain other amounts that are the result of other, non-comparable events to measure operating performance if and when present in the periods presented. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the company believes these items are not routine operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the company believes the costs associated with legal settlements and judgments are not routine operating expenses. The company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Adjusted Net Income (non-GAAP)

Adjusted net income (non-GAAP) is net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable GAAP financial measure) adjusted for asset impairments, restructuring, integration and transformation costs, acquisition-related contingent consideration, separation costs and separation-related costs and other non-GAAP adjustments, as these adjustments are described above, and further adjusted for amortization of intangible assets and acquisition-related costs and adjustments excluding amortization of intangible assets, as described below:

Amortization of intangible assets: The company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The company believes that the adjustments of these items correlate with the sustainability of the company’s operating performance. Although the company excludes the amortization of intangible assets from its non-GAAP expenses, the company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.
Acquisition-related costs and adjustments excluding amortization of intangible assets: In addition to the acquisition-related costs and adjustments as described above, the company has excluded the expense directly attributable to one-time commitment and structuring fees related to a bridge loan facility put in place prior to the acquisition of XIIDRA and certain other ophthalmology assets. The company excluded these costs as they are outside of the ordinary course of continuing operations and are infrequent in nature. The company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the company from period to period and, therefore, provides useful supplemental information to investors.

Adjusted net income (non-GAAP) excludes the impact of these certain items that may obscure trends in the company’s underlying performance. Management uses Adjusted net income (non-GAAP) for strategic decision making, forecasting future results and evaluating current performance. By disclosing this non-GAAP measure, it is management’s intention to provide investors with a meaningful, supplemental comparison of the company’s operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allows investors to evaluate the company’s performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the company’s operating performance and the valuation of the company. It is also noted that, in recent periods, our GAAP net income (loss) attributable to Bausch + Lomb Corporation was significantly lower than our Adjusted net income (non-GAAP).

Constant Currency

Constant currency change or constant currency revenue growth is a change in GAAP revenue (its most directly comparable GAAP financial measure) on a period-over-period basis adjusted for changes in foreign currency exchange rates. The company uses Constant Currency revenue (non-GAAP) and Constant Currency revenue Growth (non-GAAP) to assess performance of its reportable segments, and the company in total, without the impact of foreign currency exchange fluctuations. The company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison. Although changes in foreign currency exchange rates are part of our business, they are not within management’s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. Constant currency impact is determined by comparing 2024 reported amounts adjusted to exclude currency impact, calculated using 2023 monthly average exchange rates, to the actual 2023 reported amounts.

Adjusted EPS (non-GAAP)

Adjusted earnings per share or Adjusted EPS (non-GAAP) is calculated as Diluted income per share attributable to Bausch + Lomb Corporation (“GAAP EPS”) (its most directly comparable GAAP financial measure), adjusted for the per diluted share impact of each adjustment made to reconcile Net income (loss) attributable to Bausch + Lomb Corporation to Adjusted net income (non-GAAP) as discussed above. Like Adjusted net income (non-GAAP), Adjusted EPS (non-GAAP) excludes the impact of certain items that may obscure trends in the company’s underlying performance on a per share basis. By disclosing this non-GAAP measure, it is management’s intention to provide investors with a meaningful, supplemental comparison of the company’s results and trends for the periods presented on a diluted share basis. Accordingly, the company believes that Adjusted EPS (non-GAAP) is useful to investors in their assessment of the company’s operating performance, the valuation of the company and an investor’s return on investment. It is also noted that, for the periods presented, our GAAP EPS was significantly lower than our Adjusted EPS (non-GAAP).

FINANCIAL TABLES FOLLOW


Bausch + Lomb Corporation										Table 1
Consolidated Statements of Operations
For the Three and Six Months Ended June 30, 2024 and 2023
(unaudited)
	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions, except per share amounts)		2024			2023			2024			2023
Revenues
Product sales	$	1,213		$	1,031		$	2,307		$	1,959
Other revenues		3			4			8			7
		1,216			1,035			2,315			1,966
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)		482			417			905			788
Cost of other revenues		1			—			2			1
Selling, general and administrative		535			417			1,039			835
Research and development		84			85			166			162
Amortization of intangible assets		74			56			148			113
Other expense, net		14			17			23			26
		1,190			992			2,283			1,925
Operating income		26			43			32			41
Interest income		3			5			6			8
Interest expense		(102	)		(58	)		(201	)		(108	)
Foreign exchange and other		(3	)		(9	)		(3	)		(15	)
Loss before provision for income taxes		(76	)		(19	)		(166	)		(74	)
Provision for income taxes		(72	)		(10	)		(145	)		(43	)
Net loss		(148	)		(29	)		(311	)		(117	)
Net income attributable to noncontrolling interest		(3	)		(3	)		(7	)		(5	)
Net loss attributable to Bausch + Lomb Corporation	$	(151	)	$	(32	)	$	(318	)	$	(122	)

Basic and diluted loss per share attributable to Bausch + Lomb Corporation	$	(0.43	)	$	(0.09	)	$	(0.90	)	$	(0.35	)

Basic and diluted weighted-average common shares		351.8			350.5			351.5			350.3

Bausch + Lomb Corporation										Table 2
Reconciliation of GAAP Net Loss and Diluted Loss per Share Attributable to Bausch + Lomb Corporation to Adjusted Net Income (non-GAAP) and Adjusted Earnings Per Share (non-GAAP)
For the Three and Six Months Ended June 30, 2024 and 2023
(unaudited)
	Three Months Ended June 30,
	2024						2023
(in millions, except per share amounts)	Income (Expense)			Earnings per Share Impact			Income (Expense)			Earnings per Share Impact
Net loss and Diluted loss per share attributable to Bausch + Lomb Corporation	$	(151	)	$	(0.43	)	$	(32	)	$	(0.09	)
Non-GAAP adjustments: ^(a)
Amortization of intangible assets		74			0.21			56			0.16
Asset impairments		5			0.01			—			—
Restructuring, integration and transformation costs		27			0.08			30			0.09
Acquisition-related costs and adjustments (excluding amortization of intangible assets)		21			0.06			3			0.01
Separation costs and separation-related costs		1			—			2			—
Gain on sale of assets		(1	)		—			—			—
Other		4			0.01			2			—
Tax effect of non-GAAP adjustments		65			0.19			4			0.01
Total non-GAAP adjustments		196			0.56			97			0.27
Adjusted net income (non-GAAP) and Adjusted earnings per share (non-GAAP)	$	45		$	0.13		$	65		$	0.18


	Six Months Ended June 30,
	2024						2023
(in millions, except per share amounts)	Income (Expense)			Earnings per Share Impact			Income (Expense)			Earnings per Share Impact
Net loss and Diluted loss per share attributable to Bausch + Lomb Corporation	$	(318	)	$	(0.90	)	$	(122	)	$	(0.35	)
Non-GAAP adjustments: ^(a)
Amortization of intangible assets		148			0.42			113			0.32
Asset impairments		5			0.01			—			—
Restructuring, integration and transformation costs		55			0.15			62			0.18
Acquisition-related costs and adjustments (excluding amortization of intangible assets)		42			0.12			4			0.01
Separation costs and separation-related costs		3			0.01			5			0.01
Gain on sale of assets		(5	)		(0.01	)		—			—
Other		6			0.02			2			0.01
Tax effect of non-GAAP adjustments		133			0.38			35			0.10
Total non-GAAP adjustments		387			1.10			221			0.63
Adjusted net income (non-GAAP) and Adjusted earnings per share (non-GAAP)	$	69		$	0.20		$	99		$	0.28

(a)	The components of and further details respecting each of these non-GAAP adjustments and the financial statement line item to which each component relates can be found on Table 2a.

Bausch + Lomb Corporation							Table 2a
Reconciliation of GAAP to Non-GAAP Financial Information
For the Three and Six Months Ended June 30, 2024 and 2023
(unaudited)
	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions)		2024			2023			2024			2023
Cost of goods sold reconciliation:
GAAP Cost of goods sold (excluding amortization and impairments of intangible assets)	$	482		$	417		$	905		$	788
Fair value inventory step-up resulting from acquisitions ^(a)		(20	)		—			(40	)		—
Adjusted cost of goods sold (excluding amortization and impairments of intangible assets) (non-GAAP)	$	462		$	417		$	865		$	788
Selling, general and administrative reconciliation:
GAAP Selling, general and administrative	$	535		$	417		$	1,039		$	835
Separation-related costs ^(b)		(1	)		(2	)		(2	)		(5	)
Transformation costs ^(c)		(21	)		(16	)		(38	)		(40	)
Other ^(d)		(2	)		(1	)		(3	)		(1	)
Adjusted selling, general and administrative (non-GAAP)	$	511		$	398		$	996		$	789
Research and development reconciliation:
GAAP Research and development	$	84		$	85		$	166		$	162
Separation-related costs ^(b)		—			—			(1	)		—
Adjusted research and development (non-GAAP)	$	84		$	85		$	165		$	162
Amortization of intangible assets reconciliation:
GAAP Amortization of intangible assets	$	74		$	56		$	148		$	113
Amortization of intangible assets ^(e)		(74	)		(56	)		(148	)		(113	)
Adjusted amortization of intangible assets (non-GAAP)	$	—		$	—		$	—		$	—
Other expense, net reconciliation:
GAAP Other expense, net	$	14		$	17		$	23		$	26
Litigation and other matters ^(d)		—			—			(1	)		—
Restructuring and integration costs ^(c)		(6	)		(14	)		(17	)		(22	)
Asset impairments ^(f)		(5	)		—			(5	)		—
Acquisition-related contingent consideration ^(a)		—			(1	)		(1	)		(1	)
Acquisition-related costs ^(a)		(1	)		(2	)		(1	)		(3	)
Gain on sale of assets ^(g)		1			—			5			—
Adjusted other expense, net (non-GAAP)	$	3		$	—		$	3		$	—
Foreign exchange and other reconciliation:
GAAP Foreign exchange and other	$	(3	)	$	(9	)	$	(3	)	$	(15	)
Other ^(d)		2			1			2			1
Adjusted foreign exchange and other (non-GAAP)	$	(1	)	$	(8	)	$	(1	)	$	(14	)
Provision for income taxes reconciliation:
GAAP Provision for income taxes	$	(72	)	$	(10	)	$	(145	)	$	(43	)
Tax effect of non-GAAP adjustments ^(h)		65			4			133			35
Adjusted provision for income taxes (non-GAAP)	$	(7	)	$	(6	)	$	(12	)	$	(8	)

(a)	Represents the three components of the non-GAAP adjustment of “Acquisition-related costs and adjustments (excluding amortization of intangible assets)” (see Table 2).
(b)	Represents the two components of the non-GAAP adjustment of “Separation costs and separation-related costs” (see Table 2).
(c)	Represents the two components of the non-GAAP adjustment of “Restructuring, integration and transformation costs” (see Table 2).
(d)	Represents the three components of the non-GAAP adjustment of “Other” (see Table 2).
(e)	Represents the sole component of the non-GAAP adjustment of “Amortization of intangible assets” (see Table 2).
(f)	Represents the sole component of the non-GAAP adjustment of “Asset impairments” (see Table 2).
(g)	Represents the sole component of the non-GAAP adjustment of “Gain on sale of assets” (see Table 2).
(h)	Represents the sole component of the non-GAAP adjustment of “Tax effect of non-GAAP adjustments” (see Table 2).

Bausch + Lomb Corporation										Table 2b
Reconciliation of GAAP Net Loss to Adjusted EBITDA (non-GAAP)
For the Three and Six Months Ended June 30, 2024 and 2023
(unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions)		2024			2023			2024			2023
Net loss attributable to Bausch + Lomb Corporation	$	(151	)	$	(32	)	$	(318	)	$	(122	)
Interest expense, net		99			53			195			100
Provision for income taxes		72			10			145			43
Depreciation and amortization of intangible assets		110			93			220			184
EBITDA		130			124			242			205
Adjustments:
Asset impairments		5			—			5			—
Restructuring, integration and transformation costs		27			30			55			62
Acquisition-related costs and adjustments (excluding amortization of intangible assets)		21			3			42			4
Share-based compensation		22			18			41			42
Separation costs and separation-related costs		1			2			3			5
Other non-GAAP adjustments:
Gain on sale of assets		(1	)		—			(5	)		—
Other		4			2			6			2
Adjusted EBITDA (non-GAAP)	$	209		$	179		$	389		$	320

Bausch + Lomb Corporation															Table 3
Constant Currency Revenue (non-GAAP) and Constant Currency Revenue Growth (non-GAAP) - by Segment
For the Three and Six Months Ended June 30, 2024 and 2023
(unaudited)

	Calculation of Constant Currency Revenue for the Three Months Ended
	June 30, 2024						June 30, 2023		Change in Revenue as Reported				Change in Constant Currency Revenue (Non-GAAP) ^(b)
	Revenue as Reported		Changes in Exchange Rates^(a)		Constant Currency Revenue (Non-GAAP) ^(b)		Revenue as Reported		Change in Revenue as Reported
(in millions)	Revenue as Reported		Changes in Exchange Rates^(a)		Constant Currency Revenue (Non-GAAP) ^(b)		Revenue as Reported		Amount		Pct.		Amount		Pct.
Vision Care	$	697	$	20	$	717	$	646	$	51	8	%	$	71	11	%
Surgical		209		4		213		195		14	7	%		18	9	%
Pharmaceuticals		310		3		313		194		116	60	%		119	61	%
Total revenues	$	1,216	$	27	$	1,243	$	1,035	$	181	17	%	$	208	20	%

	Calculation of Constant Currency Revenue for the Six Months Ended
	June 30, 2024						June 30, 2023		Change in Revenue as Reported				Change in Constant Currency Revenue (Non-GAAP) ^(b)
	Revenue as Reported		Changes in Exchange Rates^(a)		Constant Currency Revenue (Non-GAAP) ^(b)		Revenue as Reported		Change in Revenue as Reported
(in millions)	Revenue as Reported		Changes in Exchange Rates^(a)		Constant Currency Revenue (Non-GAAP) ^(b)		Revenue as Reported		Amount		Pct.		Amount		Pct.
Vision Care	$	1,332	$	38	$	1,370	$	1,233	$	99	8	%	$	137	11	%
Surgical		406		5		411		378		28	7	%		33	9	%
Pharmaceuticals		577		4		581		355		222	63	%		226	64	%
Total revenues	$	2,315	$	47	$	2,362	$	1,966	$	349	18	%	$	396	20	%

(a)

The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

(b)

To supplement the financial measures prepared in accordance with GAAP, the Company uses certain non-GAAP financial measures and ratios. For additional information about the Company’s use of such non-GAAP financial measures and ratios, refer to the “Non-GAAP Information” section in the body of the news release to which these tables are attached. Constant currency revenue (non-GAAP) for the three and six months ended June 30, 2024 is calculated as revenue as reported adjusted for the impact for changes in exchange rates (previously defined in this news release). Change in constant currency revenue (non-GAAP) is calculated as the difference between constant currency revenue for the current period and revenue as reported for the comparative period.

_____________________________________
¹	This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the most directly comparable GAAP measure.
²	The guidance in this news release is only effective as of the date given, July 31, 2024, and will not be updated or affirmed unless and until the company publicly announces updated or affirmed guidance. Distribution or reference of this news release following July 31, 2024, does not constitute the company reaffirming guidance. See the “Forward-looking Statements” section for further information.
³	The increase in anticipated full-year revenue, anticipated constant currency revenue growth and anticipated Adjusted EBITDA is a result of the strength of the performance of our business across all segments in the second quarter, as well as result of an increase in our expected MIEBO revenues for the remainder of 2024, partially offset by a change in our expected XIIDRA revenues for 2024.
⁴	Diluted weighted average shares includes the dilutive impact of options, performance based restricted stock units and restricted stock units, which are approximately 1,200,000 common shares for the 3 months ended June 30, 2024, and which are excluded when calculating GAAP diluted loss per share because the effect of including the impact would be anti-dilutive.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731856539/en/

Media Contact:

T.J. Crawford

tj.crawford@bausch.com

(908) 705-2851

Investor Contact:

George Gadkowski

george.gadkowski@bausch.com

(877) 354-3705 (toll free)

(908) 927-0735

Source: Bausch + Lomb Corporation

FAQ

What was Bausch + Lomb's (BLCO) revenue for Q2 2024?

Bausch + Lomb (BLCO) reported revenue of $1.216 billion for Q2 2024, representing a 17% increase as reported and 20% on a constant currency basis compared to Q2 2023.

How did Bausch + Lomb's (BLCO) business segments perform in Q2 2024?

In Q2 2024, Bausch + Lomb's Vision Care revenue was $697 million (up 8%), Surgical revenue was $209 million (up 7%), and Pharmaceuticals revenue was $310 million (up 60%).

What was Bausch + Lomb's (BLCO) net income/loss for Q2 2024?

Bausch + Lomb (BLCO) reported a GAAP net loss of $151 million for Q2 2024, compared to a net loss of $32 million in Q2 2023.

Has Bausch + Lomb (BLCO) updated its 2024 financial guidance?

Yes, Bausch + Lomb (BLCO) raised its full-year 2024 revenue guidance to $4.700 - $4.800 billion and Adjusted EBITDA guidance to $850 - $900 million.

What was Bausch + Lomb's (BLCO) Adjusted EBITDA for Q2 2024?

Bausch + Lomb (BLCO) reported Adjusted EBITDA of $209 million for Q2 2024, an increase from $179 million in Q2 2023.

Bausch + Lomb Announces Second-Quarter 2024 Results

Insights

FAQ

What was Bausch + Lomb's (BLCO) revenue for Q2 2024?

How did Bausch + Lomb's (BLCO) business segments perform in Q2 2024?

What was Bausch + Lomb's (BLCO) net income/loss for Q2 2024?

Has Bausch + Lomb (BLCO) updated its 2024 financial guidance?

What was Bausch + Lomb's (BLCO) Adjusted EBITDA for Q2 2024?

NYSE:BLCO

BLCO Rankings

BLCO Latest News

BLCO Stock Data

Trending News

Bausch + Lomb Announces Second-Quarter 2024 Results

Insights

Financial Analyst positive

Market Research Analyst positive

FAQ

What was Bausch + Lomb's (BLCO) revenue for Q2 2024?

How did Bausch + Lomb's (BLCO) business segments perform in Q2 2024?

What was Bausch + Lomb's (BLCO) net income/loss for Q2 2024?

Has Bausch + Lomb (BLCO) updated its 2024 financial guidance?

What was Bausch + Lomb's (BLCO) Adjusted EBITDA for Q2 2024?

NYSE:BLCO

BLCO Rankings

BLCO Latest News

BLCO Stock Data